FDA Modernization Act 3.0
Latest Action
Held at the desk.
Official Summary
FDA Modernization Act 3.0 This bill requires the Food and Drug Administration (FDA) to publish an interim final rule implementing a provision of the Consolidated Appropriations Act of 2023 that authorized the use of certain alternatives to animal testing to support investigational use of a new drug. The rule must replace references to animal tests, data, studies, models, and research with references to nonclinical tests, data, studies, models, and research throughout the FDA’s regulations governing investigational new drug applications, and may make other changes to the regulations as appropriate. The rule must be published within one year of the bill’s enactment, and must take immediate effect as an interim final rule.
GovScope Watchdog™
AI Government Intelligence™The FDA Modernization Act 3.0 is a Senate bill introduced in the 119th Congress aimed at updating and reforming the regulatory framework of the Food and Drug Administration. The bill is currently in process but lacks publicly available details such as an official summary or full text. Its latest recorded action is that it was held at the desk as of December 17, 2025. Without the bill text or summary, specific provisions, goals, or mechanisms of the legislation cannot be described.
This bill proposes modernization of FDA regulations but lacks publicly available details, making it difficult to assess its specific content or impact at this time.
- The bill is titled FDA Modernization Act 3.0 and was introduced in the Senate during the 119th Congress.
- No official summary or full text is currently available to describe the bill's provisions.
- The latest procedural status is 'Held at the desk' as of December 17, 2025, indicating no recent legislative movement.
['Potential beneficiaries could include the FDA as an agency, regulated industries such as pharmaceuticals and medical devices, and ultimately consumers, but specific beneficiaries cannot be identified without bill details.']
["Lack of publicly available text or summary limits transparency and public understanding of the bill's scope and implications.", 'Without details, it is unclear what implementation challenges, costs, or oversight mechanisms the bill entails.', "The status 'Held at the desk' may indicate legislative delays or procedural hurdles."]
The bill is part of ongoing efforts to update FDA regulatory processes, reflecting continued congressional interest in modernizing health and safety oversight. However, the absence of detailed information and recent legislative activity suggests it has not advanced significantly in the legislative process.
Hidden impact flags detected: 2
GovScope reviewed 2 policy-risk categories. Hover for a quick definition. Click detected flags for bill-specific details.
['If enacted, the bill could influence FDA regulatory procedures, potentially affecting drug and device approval timelines and industry compliance requirements.', 'Modernization efforts may lead to shifts in resource allocation within the FDA and among regulated entities.', 'Delays or lack of clarity in the legislative process may prolong uncertainty for stakeholders.']
The absence of publicly available bill text and summary significantly limits transparency and public oversight. Monitoring future updates is essential to assess the bill's provisions and impacts. The stalled legislative status suggests limited current momentum, underscoring the importance of tracking procedural developments.
GovScope Intelligence Roadmap
Future bill intelligence will connect sponsors, committee referrals, related votes, campaign finance, disclosures, and stock trades into one legislative intelligence view.